Endocrine therapy of Breast Cancer
- Prosjektnummer
- 911625
- Ansvarlig person
- Ernst A.Lien
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Forskningsprosjekt
- Helsekategori
- Cancer
- Forskningsaktivitet
- 5. Treatment Developement
Illness uncertainty in breast cancer patients: validation of the 5-item short form of the Mishel Uncertainty in Illness Scale.
Eur J Oncol Nurs 2015 Apr;19(2):113-9. Epub 2014 des 20
PMID: 25538036
Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment.
Breast Cancer Res Treat 2013 Sep;141(2):243-8. Epub 2013 sep 1
PMID: 23996142
cAMP response element-binding protein interacts with and stimulates the proteasomal degradation of the nuclear receptor coactivator GRIP1.
Endocrinology 2013 Apr;154(4):1513-27. Epub 2013 mar 5
PMID: 23462962
Breaking away: high fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients.
Acta Oncol 2013 May;52(4):861-2. Epub 2012 nov 29
PMID: 23193962
Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer.
BMC Cancer 2012;12():247. Epub 2012 jun 15
PMID: 22703232
Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.
Breast Cancer Res Treat 2012 Jul;134(2):693-700. Epub 2012 mai 5
PMID: 22562123
Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer.
Ann Oncol 2011 Mar;22(3):582-7. Epub 2010 aug 17
PMID: 20716629
Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.
Pharmacogenomics J 2011 Apr;11(2):100-7. Epub 2010 mar 23
PMID: 20309015
Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.
Cancer Epidemiol Biomarkers Prev 2011 Sep;20(9):1937-43. Epub 2011 jul 12
PMID: 21750172
Tamoxifen metabolism and biological activity. Tamoxifen: Properties, Biological Activity and Health Benefits.
Nova Publishers Inc, New York, USA. 2012
Breaking away: High fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients.
Acta Oncol., DOI 10.3109/0284186X.2012.742963, 2012
Steroid receptor coactivatorsand their expression, regulation and functinal role in endocrine responsive and resistant breast ca
Breast cancer cells, editor Gunduz M. InTech Open Access Publisher, ISBN 978-953-307-351-4, Rijeka, Croatia.
Steroid receptor coactivators and endocrine treatment in breast cancer
Nuclear Receptors: Structure, mechanisms of action and disease, editors Bates MK and Kerr RM, pp. 35-66. Nova Publishers Inc, ISBN 978-61209-980-4, New York, USA.
Endocrine treatment of breast cancer. Tamoxifen metabolism, steroid receptor coactivators and growth factor receptors
- Disputert:
- januar 2012
- Hovedveileder:
- Gunnar Mellgren
Steroid receptor coactivators and epidermal growth factor receptors in breast cancer
- Disputert:
- april 2011
- Hovedveileder:
- Gunnar Mellgren
- Jennifer Gjerde Prosjektdeltaker
- Ernst Asbjørn Lien Prosjektleder
- Turid Aas Prosjektdeltaker
- Gunnar Mellgren Prosjektdeltaker
- Håvard Søiland Prosjektdeltaker
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest